Payment overview · 2025
General Payments
$101.00
5 reported records · 4 companies
Healthcare provider profile · identity verified
Tiffany Jones, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · MENTOR, OH · NPI 1003082413
Verified facts
What the public records show
CMS Open Payments records show Tiffany Jones, M.D. received $101.00 in general payments during 2025 across 5 reported records.
Daiichi Sankyo Inc. accounted for 47.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $47.47 | 47.0% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.02 | 19.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.92 | 18.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.59 | 14.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $101.00 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Enhertu Normalized: enhertu |
Drug | Daiichi Sankyo Inc. | $47.47 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| FYLNETRA Normalized: fylnetra |
Drug | Amneal Pharmaceuticals LLC | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Risperidone | Risperidone | 521 | 45 |
| Benztropine Mesylate | Benztropine Mesylate | 508 | 66 |
| Olanzapine | Olanzapine | 365 | 44 |
| Quetiapine Fumarate | Quetiapine Fumarate | 344 | 47 |
| Aripiprazole | Aripiprazole | 315 | 46 |
| Invega Sustenna | Paliperidone Palmitate | 293 | 30 |
| Haloperidol Decanoate | Haloperidol Decanoate | 286 | 28 |
| Divalproex Sodium Er | Divalproex Sodium | 278 | 34 |
| Buspirone Hcl | Buspirone Hcl | 254 | 37 |
| Haloperidol | Haloperidol | 241 | 27 |
| Lamotrigine | Lamotrigine | 217 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 211 | 28 |
| Sertraline Hcl | Sertraline Hcl | 193 | 23 |
| Trazodone Hcl | Trazodone Hcl | 192 | 28 |
| Divalproex Sodium | Divalproex Sodium | 185 | 26 |
| Bupropion Xl | Bupropion Hcl | 179 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 176 | 26 |
| Lorazepam | Lorazepam | 152 | 22 |
| Mirtazapine | Mirtazapine | 146 | 22 |
| Clonazepam | Clonazepam | 134 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 25 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 122 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 12 |
| Diazepam | Diazepam | 88 | 11 |
| Lithium Carbonate | Lithium Carbonate | 85 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 84 | 16 |
| Paliperidone Er | Paliperidone | 82 | 17 |
| Alprazolam | Alprazolam | 75 | suppressed |
| Abilify Maintena | Aripiprazole | 74 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 74 | 12 |
| Temazepam | Temazepam | 70 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | suppressed |
| Gabapentin | Gabapentin | 67 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | suppressed |
| Rexulti | Brexpiprazole | 57 | suppressed |
| Amantadine | Amantadine Hcl | 54 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 48 | suppressed |
| Zaleplon | Zaleplon | 48 | 13 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 44 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Vraylar | Cariprazine Hcl | 43 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 42 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 42 | 16 |
| Methylphenidate Hcl | Methylphenidate Hcl | 42 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 42 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 42 | suppressed |
| Belsomra | Suvorexant | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 38 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 35 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 34 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 30 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 30 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 29 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Thiothixene | Thiothixene | 24 | suppressed |
| Caplyta | Lumateperone Tosylate | 23 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 21 | suppressed |
| Fanapt | Iloperidone | 20 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Austedo | Deutetrabenazine | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Perphenazine | Perphenazine | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $101.00 · 5 records | Daiichi Sankyo Inc. | Enhertu, FRUZAQLA, FYLNETRA, UZEDY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Takeda Pharmaceuticals U.S.A., Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error